SEARCH

SEARCH BY CITATION

References

  • 1
    Bray GL, Gomperts ED, Courter S, Gruppo R, Gordon EM, Manco-Johnson M, Shapiro A, Scheibel E, White G 3rd, Lee M. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood 1994; 83: 242835.
  • 2
    Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, Gungor T, Krackhardt B, Kornhuber B. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 5948.
  • 3
    Ljung R, Petrini P, Lindgren AC, Tengborn L, Nilsson IM. Factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 1550.
  • 4
    Addiego J, Kasper C, Abildgaard C, Hilgartner M, Lusher J, Glader B, Aledort L. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII. Lancet 1993; 342: 4624.
  • 5
    Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med 1993; 328: 4539.
  • 6
    De Biasi R, Rocino A, Papa ML, Salerno E, Mastrullo L, De Blasi D. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates. Thromb Haemost 1994; 71: 5447.
  • 7
    Lusher JM. Viral safety and inhibitor development associated with monoclonal antibody-purified F VIII C. Ann Hematol 1991; 63: 13841.
  • 8
    Hay CR, Ludlam CA, Colvin BT, Hill FG, Preston FE, Wasseem N, Bagnall R, Peake IR, Berntorp E, Mauser Bunschoten EP, Fijnvandraat K, Kasper CK, White G, Santagostino E. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation. Thromb Haemost 1998; 79: 7626.
  • 9
    Diamondstone LS, Aledort LM, Goedert JJ. Factors predictive of death among HIV-uninfected persons with haemophilia and other congenital coagulation disorders. Haemophilia 2002; 8: 6607.
  • 10
    Ikkala E, Helske T, Myllyla G, Nevanlinna HR, Pitkanen P, Rasi V. Changes in the life expectancy of patients with severe haemophilia A in Finland In 1930–79. Br J Haematol 1982; 52: 712.
  • 11
    Larsson SA. Life expectancy of Swedish haemophiliacs, 1831–1980. Br J Haematol 1985; 59: 593602.
  • 12
    Rizza CR, Spooner RJ. Treatment of haemophilia and related disorders in Britain and Northern Ireland during 1976–80: report on behalf of the directors of haemophilia centres in the United Kingdom. BMJ 1983; 286: 92933.
  • 13
    Rosendaal FR, Varekamp I, Smit C, Brocker-Vriends AH, Van Dijck H, Vandenbroucke JP, Hermans J, Suurmeijer TP, Briet E. Mortality and causes of death in Dutch haemophiliacs, 1973–86 Br J Haematol 1989; 71: 716.
  • 14
    Triemstra M, Rosendaal FR, Smit C, Van der Ploeg HM, Briet E. Mortality in patients with hemophilia. Changes in a Dutch population from 1986 to 1992 and 1973 to 1986. Ann Intern Med 1995; 123: 8237.
  • 15
    Rasi V, Ikkala E. Haemophiliacs with factor VIII inhibitors in Finland. prevalence, incidence and outcome. Br J Haematol 1990; 76: 36971.
  • 16
    United Kingdom Haemophilia Doctors' Organisation. The impact of HIV on mortality rates in the UK haemophilia population. AIDS 2003,in press .
  • 17
    Darby SC, Ewart DW, Giangrande PL, Dolin PJ, Spooner RJ, Rizza CR. Mortality before and after HIV infection in the complete UK population of haemophiliacs. Nature 1995; 377: 7982.
  • 18
    StataCorp. Stata Statistical Software. Release 5.0. Stata Corporation: College Station, TX; 1997.
  • 19
    Colvin BT, Hay CRM, Hill FGH, Preston FE. The incidence of factor VIII inhibitors in the UK, 1990–93. Br J Haematol, 1995; 89: 90810.
  • 20
    Rizza CR, Spooner RJD, Giangrande PLF. Treatment of haemophilia In United Kingdom 1981–96. Haemophilia 2001; 7: 34959.
  • 21
    United Kingdom Haemophilia Centre Doctors' Organisation. Reports on the Annual Returns 1997, 1998, 1999. UKHCDO, Oxford 1997, 2000, 2001.
  • 22
    Sjamsoedin LJ, Heijnen L, Mauser-Bunschoten EP, Van Geijlswijk JL, Van Houwelingen H, Van Asten P, Sixma JJ. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial. N Engl J Med 1981; 305: 71721.
  • 23
    Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. Thromb Haemost 1997; 77: 11139.
  • 24
    Lusher J, Ingerslev J, Roberts H, Hedner U. Clinical experience with recombinant factor VIIa. Blood Coagul Fibrinolysis 1998; 9: 11928.
  • 25
    Ragni MV, Bontempo FA, Lewis JH. Disappearance of inhibitor to factor VIII in HIV-infected hemophiliacs with progression to AIDS or severe ARC. Transfusion 1989; 29: 4479.
  • 26
    Leyva WH, Knutsen AP, Joist JH. Disappearance of a high response factor VIII inhibitor in a hemophiliac with AIDS. Am J Clin Pathol 1988; 89: 4148.
  • 27
    Gringeri A, Mantovani L, Salone L, Mannucci PM. Cost of care and quality of life in hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102: 235863.